Prelude Therapeutics appoints Katina Dorton to board of directors

WILMINGTON, Del. - Prelude Therapeutics Incorporated (NASDAQ:PRLD), a precision oncology company with a market capitalization of approximately $100 million, announced Friday the appointment of Katina Dorton to its Board of Directors, effective immediately. Dorton will also assume the role of Audit Committee Chair, succeeding Mardi C. Dier, who is resigning from the board after serving since August 2020.

Dorton brings over 30 years of experience in healthcare and life sciences to the clinical-stage precision oncology company. She most recently served as Chief Financial Officer at NodThera and previously led finance at Repare Therapeutics, where she prepared the company for an IPO and raised more than $82 million in crossover funding. According to InvestingPro data, Prelude maintains a strong liquidity position with a current ratio of 3.68, though the company is currently experiencing rapid cash burn.

Her background includes senior finance positions at AVROBIO, Inc. and Immatics N.V., as well as 15 years as an investment banker with Morgan Stanley and Needham & Co. Dorton currently serves on the boards of Mallinckrodt Pharmaceuticals plc, Fulcrum Therapeutics, TScan Therapeutics, and Sonoma Biotherapeutics.

"Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," said Kris Vaddi, Chief Executive Officer of Prelude, in the press release statement. For detailed analysis of Prelude’s financial position and growth trajectory, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro.

Dorton holds a B.A. from Duke University, an M.B.A. from George Washington University, and a J.D. from the University of Virginia School of Law.

Prelude Therapeutics is focused on developing precision oncology medicines, with a pipeline that includes SMARCA2 and KAT6A degraders. The company is also working on precision degrader antibody conjugates (Precision ADCs) through partnerships.

In other recent news, Prelude Therapeutics has regained compliance with the Nasdaq’s minimum bid price rule. The company received confirmation from Nasdaq on September 18, 2025, that it now meets the listing standard, which requires a minimum bid price of $1.00 per share. This follows a notification on March 27, 2025, when Prelude Therapeutics was informed of its non-compliance due to its stock price falling below the required threshold. Additionally, H.C. Wainwright has reiterated its Buy rating for Prelude Therapeutics, maintaining a price target of $5.00. The firm cited upcoming catalysts expected by the end of 2025, including the presentation of final results from the Phase 1 trial evaluating PRT3789 in SMARCA4-mutated cancers. Initial interim data from the Phase 1 trial of PRT7732, an orally bioavailable SMARCA2 degrader, is also anticipated. These developments are part of Prelude Therapeutics’ ongoing efforts to advance its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.